HL-5101 is under clinical development by AUM Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HL-5101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HL-5101 overview

HL-5101 (NOV-1601) is under development for the treatment of solid tumors, primary central nervous system(CNS) tumors, NTRK fusion and mutant cancers like colorectal cancer, head and neck cancer and non-small cell lung cancer. It is a new chemical entity. It is administered through oral route. The drug candidate acts by targeting Pan-TRK (TRKA, TRKB, TRKC).

AUM Biosciences overview

AUM Biosciences is a biotechnology company that discovers, develops and commercializes precision medicines to treat cancer. It is investigating AUM001+Keytruda against microsatellite stable (MSS) colorectal cancer; and AUM001+tecentriq for the treatment of multiple solid tumors. The company is also evaluating AUM601 to treat TRK fusion and mutation tumor agnostic; AUM302 for PIM over expression and PIK3CA mutation; and AUM003 targeting glioblastoma and sarcoma. It operates with additional offices in Jiangsu, China; Maryland, the US; and Victoria, Australia. AUM Biosciences is headquartered in Singapore City, Singapore.

For a complete picture of HL-5101’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.